Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.

MLA

Magro, Fernando, et al. “Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-Stable Ulcerative Colitis Patients Are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.” EBioMedicine, vol. 21, July 2017, pp. 123–30. EBSCOhost, https://doi.org/10.1016/j.ebiom.2017.06.004.

APA

Magro, F., Afonso, J., Lopes, S., Coelho, R., Gonçalves, R., Caldeira, P., Lago, P., de Sousa, H. T., Ramos, J., Gonçalves, A. R., Ministro, P., Rosa, I., Vieira, A. I., Andrade, P., Soares, J.-B., Carvalho, D., Sousa, P., Meira, T., Lopes, J., … Carneiro, F. (2017). Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation. EBioMedicine, 21, 123–130. https://doi.org/10.1016/j.ebiom.2017.06.004

Chicago

Magro, Fernando, Joana Afonso, Susana Lopes, Rosa Coelho, Raquel Gonçalves, Paulo Caldeira, Paula Lago, et al. 2017. “Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-Stable Ulcerative Colitis Patients Are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.” EBioMedicine 21 (July): 123–30. doi:10.1016/j.ebiom.2017.06.004.